Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Sexually Transmitted Diseases 1Papillomavirus Infections 1Mesothelioma, Malignant 1Lung Neoplasms 1Condylomata Acuminata 1Carcinoma, Non-Small-Cell Lung 1

Interventions

ranpirnase 1VP-102 1Therapies, Investigational 1Imiquimod 1Gels 1Electrocoagulation 1Community Health Workers 1Colposcopy 1Circumcision, Male 1Cantharidin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Sexually Transmitted Diseases × ranpirnase × Clear all
NCT02535104 2018-06-06

Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)

Tamir Biotechnology, Inc.

Phase 1/2 Completed
70 enrolled

Condylomata Acuminata, Sexually Transmitted Diseases, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡